ULISSE BIOMED S.P.A. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.19 EUR | 0.00% |
|
+8.18% | -28.10% |
| May. 09 | Ulisse Biomed, Sbaizero resigns as independent director | AN |
| May. 03 | Ulysses Biomed reduces loss in 2023; NFP is positive | AN |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 24.11 | 8.209 | 25.67 | 25.67 | - |
| Enterprise Value (EV) 1 | 19.12 | 4.415 | 23.48 | 23.3 | 22.78 |
| P/E ratio | - | - | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 58.1 x | 15.7 x | 75.3 x | 18.1 x | 15 x |
| EV / Revenue | 46.1 x | 8.43 x | 68.8 x | 16.4 x | 13.4 x |
| EV / EBITDA | -53.7 x | -4.47 x | -15.8 x | 37.3 x | 25.1 x |
| EV / FCF | -13.5 x | -4.21 x | -14.7 x | 139 x | 43.8 x |
| FCF Yield | -7.38% | -23.8% | -6.82% | 0.72% | 2.28% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 7,250 | 8,064 | 21,570 | 21,570 | - |
| Reference price 2 | 3.325 | 1.018 | 1.190 | 1.190 | 1.190 |
| Announcement Date | 3/28/22 | 3/28/23 | - | - | - |
1EUR in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.7627 | 0.4148 | 0.5238 | 0.341 | 1.421 | 1.706 |
| EBITDA 1 | - | -0.3557 | -0.9868 | -1.483 | 0.625 | 0.909 |
| EBIT 1 | - | -0.6034 | -1.306 | -1.821 | 0.264 | 0.524 |
| Operating Margin | - | -145.47% | -249.42% | -534.02% | 18.58% | 30.72% |
| Earnings before Tax (EBT) | - | -0.6036 | -1.308 | - | - | - |
| Net income 1 | 0.2218 | -0.6036 | -1.308 | -1.814 | 0.269 | 0.53 |
| Net margin | 29.09% | -145.51% | -249.68% | -531.96% | 18.93% | 31.07% |
| EPS | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -1.411 | -1.049 | -1.602 | 0.168 | 0.52 |
| FCF margin | - | -340.22% | -200.23% | -469.79% | 11.82% | 30.48% |
| FCF Conversion (EBITDA) | - | - | - | - | 26.88% | 57.21% |
| FCF Conversion (Net income) | - | - | - | - | 62.45% | 98.11% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/8/21 | 3/28/22 | 3/28/23 | - | - | - |
1EUR in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 |
|---|---|
| Net sales | - |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) 1 | -0.8996 |
| Net income 1 | -0.8996 |
| Net margin | - |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | 9/29/23 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 4.99 | 3.79 | 2.19 | 2.37 | 2.89 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -1.41 | -1.05 | -1.6 | 0.17 | 0.52 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 1.04 | 0.08 | 0.15 | 0.1 | 0.1 |
| Capex / Sales | - | 251.26% | 14.95% | 44.28% | 7.04% | 5.86% |
| Announcement Date | 8/8/21 | 3/28/22 | 3/28/23 | - | - | - |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.10% | 27.7M | |
| +26.37% | 48.16B | |
| -1.01% | 41.73B | |
| +42.95% | 41.03B | |
| -5.31% | 28.77B | |
| +9.34% | 25.59B | |
| -21.69% | 18.96B | |
| +6.23% | 12.92B | |
| +26.99% | 12.03B | |
| -3.38% | 11.77B |
- Stock Market
- Equities
- UBM Stock
- Financials Ulisse Biomed S.p.A.